Binimetinib
Sign in to save this workspacePrimary targets: MEK1, MEK2 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.689
CATDS
0.063
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Binimetinib. Strongest target: MEK1 at 79.1% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | MEK1 | 79.1% | 20.9% |
| 2 | MEK2 | 43.5% | 56.5% |
| 3 | CDK9_CYCLIN_T1 | 33.3% | 66.7% |
| 4 | CAMKK2 | 23.0% | 77.0% |
| 5 | EGFR | 21.8% | 78.3% |
| 6 | ALK3_BMPR1A | 20.2% | 79.8% |
| 7 | TTBK2 | 20.0% | 80.0% |
| 8 | TGFBR2 | 19.7% | 80.3% |
| 9 | PDK2_PDHK2 | 16.9% | 83.1% |
| 10 | MUSK | 15.4% | 84.6% |
| 11 | CAMK2A | 15.4% | 84.6% |
| 12 | LYN | 15.4% | 84.6% |
| 13 | HASPIN | 14.4% | 85.6% |
| 14 | HIPK1 | 13.9% | 86.1% |
| 15 | VRK2 | 13.3% | 86.7% |
| 16 | VRK1 | 12.5% | 87.5% |
| 17 | P38A_MAPK14 | 12.3% | 87.7% |
| 18 | STK21_CIT | 12.2% | 87.8% |
| 19 | BRAF | 12.2% | 87.8% |
| 20 | PHKG1 | 11.5% | 88.5% |
Selectivity landscape
Where Binimetinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Binimetinib.
Annotations
Sign in to read and post annotations.
Loading…